LUV Green LifeLUV Green Life
  • Home
  • Heart Health
  • Brain Health
  • Immune Support
  • Colon Cleanse Detox
  • Weight Loss
  • Reviews
  • Shop

Subscribe to Updates

Get the latest creative news from FooBar about art, design and business.

What's Hot

5 Best Yoga Poses for Your Lower Body and Brain Health

March 15, 2023

Top 5 Herbs to Kill Viruses and Boost Your Immune System

March 15, 2023

Intermittent Fasting and Its Effects on the Brain | Ep. 82

March 14, 2023
Facebook Twitter Instagram
LUV Green LifeLUV Green Life
Facebook Twitter Instagram
SUBSCRIBE
  • Home
  • Heart Health
  • Brain Health
  • Immune Support
  • Colon Cleanse Detox
  • Weight Loss
  • Reviews
  • Shop
LUV Green LifeLUV Green Life
Home » MESO NUMISMATICS, INC. Management’s Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
Immune Support

MESO NUMISMATICS, INC. Management’s Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)

adminBy adminNovember 9, 2022Updated:November 9, 2022No Comments13 Mins Read
Facebook Twitter Pinterest LinkedIn Tumblr Reddit WhatsApp Email
Share
Facebook Twitter LinkedIn Pinterest WhatsApp Email


Forward-Looking Statements




Certain statements, apart from purely historic data, together with
estimates, projections, statements referring to our enterprise plans, targets,
and anticipated working outcomes, and the assumptions upon which these statements
are based mostly, are "forward-looking statements" inside the which means of the Private
Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of
1933 and Section 21E of the Securities Exchange Act of 1934.  These
forward-looking statements usually are recognized by the phrases "believes,"
"project," "expects," "anticipates," "estimates," "intends," "strategy," "plan,"
"may," "will," "would," "will be," "will continue," "will likely result," and
related expressions. We intend such forward-looking statements to be coated by
the safe-harbor provisions for forward-looking statements contained within the
Private Securities Litigation Reform Act of 1995, and are together with this
assertion for functions of complying with these safe-harbor
provisions. Forward-looking statements are based mostly on present expectations and
assumptions which are topic to dangers and uncertainties which can trigger precise
outcomes to vary materially from the forward-looking statements. Our skill to
predict outcomes or the precise impact of future plans or methods is inherently
unsure. Factors which may have a cloth adversarial impact on our operations
and future prospects on a consolidated foundation embrace, however aren't restricted to:
modifications in financial circumstances, legislative/regulatory modifications, availability of
capital, rates of interest, competitors, cybersecurity, and usually accepted
accounting ideas. These dangers and uncertainties must also be thought of
in evaluating forward-looking statements and undue reliance shouldn't be positioned
on such statements. We undertake no obligation to replace or revise publicly any
forward-looking statements, whether or not in consequence of new data, future
occasions or in any other case. Further, data regarding our enterprise, together with
extra elements that would materially have an effect on our monetary outcomes, is
included herein and in our different filings with the SEC.



Overview



Since the acquisition of Global Stem Cell Group in August final yr, our focus
has been primarily devoted to its operations serving the markets within the
regenerative drugs trade. We nonetheless have numismatics operation, however the
total plan for the corporate is simply too transfer from the sale of cash, paper foreign money,
bullion and medals into what we imagine is a extra profitable alternative for
our
firm.



We work with medical doctors and their employees to supply merchandise, options, tools,
companies, and coaching to assist them achieve success within the software of Stem
Cell Therapies. Our group combines options from intensive scientific analysis
with the manufacturing and commercialization of viable cell remedy and immune
assist associated merchandise that we imagine will change the course of conventional
drugs all over the world endlessly. Our technique permits us the power to create
quick income streams by means of product gross sales, distribution, and scientific
functions, pushed by our intensive schooling platform. Our income comes
instantly from the coaching and the seminars, from the resale of these kits,
merchandise, and tools, companies, and from the reoccurring software of our
course of utilizing the kits and options we offer.



                                 Page 29 of 42





Global Stem Cells Group is a pacesetter within the Stem Cell and Regenerative Medicine
fields, protecting scientific analysis, affected person functions, together with doctor
coaching by means of our state-of-the-art international community of corporations. The Company's
mission is to allow physicians to make the advantages of stem cell drugs a
actuality for sufferers all over the world. They have been educating medical doctors on the
science and software of cell-based therapeutics for the previous 10 years. Our
skilled trademarked affiliation "ISCCA" INTERNATIONAL SOCIETY FOR STEM CELL
APPLICATION is a worldwide community of medical professionals that leverages these
multinational relationships to construct greatest practices and additional our mission.



The Company envisions the power to enhance “health-span” by means of the invention
and developments of new mobile remedy merchandise, and cutting-edge expertise.

Global Stem Cells Group, as virtually everybody else on this planet, was severely
affected by the covid 19 pandemic. As we glance to get well in 2022, we’re
integrating each side of the regenerative drugs trade. During 2022, we
plan so as to add manufacturing and commercialization of viable cell remedy and
immune assist associated merchandise that we imagine will change the course of
conventional drugs all over the world endlessly.

We imagine this technique will enable us the power to extend our present
revenues and create quick income streams by means of product gross sales,
distribution, and scientific functions, pushed by our intensive schooling
platform listed below are our foremost tasks and income turbines for 2022 and past.




Results of Operations



Results of Operations for the Three Months Ended September 30, 2022 and 2021.

Below is a abstract of the outcomes of operations for the three months ended
September 30, 2022 and 2021.



                                        For the Three Months Ended September 30,
                                  2022             2021           $ Change       % Change
Revenue                       $    374,359     $    165,042     $    209,317        126.83 %
Cost of income                    109,364           88,520           20,844         23.55 %
Gross revenue                       264,995           76,522          188,473        246.30 %

Operating bills
Advertising and advertising and marketing           80,931           22,351           58,580        262.09 %
Professional charges                  143,118          336,299         (193,181 )      -57.44 %
Officer compensation                22,500          518,833         (496,333 )      -95.66 %
Depreciation and
amortization expense                39,882           12,947           26,935        208.04 %
Investor relations                  32,749           32,574              175          0.54 %
General and administrative-
associated celebration                            -        8,116,269       (8,116,269 )        -100 %
General and administrative         107,908           52,651           55,257        104.95 %
Total working bills           427,088        9,091,924       

(8,664,836 ) -95.30 %


Other revenue (expense)
Interest expense                (1,183,166 )       (900,039 )       (283,127 )       31.46 %
Derivative monetary
devices                            876                -              876            00 %
Net loss                      $ (1,344,383 )   $ (9,915,441 )   $  8,571,058        -86.44 %




                                 Page 30 of 42





Revenue


Revenue elevated by 126.83% within the quantity of $209,317 for the three months
ended September 30, 2022, in comparison with the identical interval in 2021. The key motive
for the rise in income was a outcome of the acquisition of Global Stem Cells
Group, Inc. on August 18, 2021. Revenue from viable cell remedy and immune
assist associated merchandise together with doctor coaching elevated by $214,114
offset by a lower in sale of cash, metals and paper cash of $4,797 for the
three months ended September 30, 2022, in comparison with the identical interval in 2021.

Listed beneath are the revenues, price of revenues and gross income by Company for
the three months ended September 30, 2022:



                           For the Three Months Ended
                               September 30, 2022
                   Global Stem          Meso
                   Cells Group       Numismatics        Total
Revenue           $     367,697     $       6,662     $ 374,359
Cost of income         102,779             6,585       109,364
Gross revenue      $     264,918     $          77     $ 264,995
Gross revenue %            72.05 %            1.16 %       70.79 %




We anticipate to extend our revenues in future quarters from our operations
related to Global Stem Cells with much less anticipated revenues in future quarters
related to our numismatic operations.



Operating bills



Operating bills decreased by 95% within the quantity of $8,664,836 for the three
months ended September 30, 2022, in comparison with the identical interval in 2021. Listed
beneath are the key modifications to working bills:



Advertising and advertising and marketing charges elevated by $58,580 for the three months ended
September 30, 2022, in comparison with the identical interval in 2021, primarily because of the
acquisition of Global Stem Cells Group, Inc. on August 18, 2021.



Professional charges decreased by $193,181 for the three months ended September 30,
2022, in comparison with the identical interval in 2021, primarily on account of audit and accounting
bills because of the acquisition of Global Stem Cells Group, Inc. on August
18,
2021.



Officer compensation decreased by $496,333 for the three months ended September
30, 2022, in comparison with the identical interval in 2021, primarily because of the issuance of
896 shares of Series DD Preferred Stock of the Company to Dave Christensen,
present Director, President, Chief Executive Officer, Chief Financial Officer
and Secretary as compensation pursuant to the Professional Service Consulting
Agreement. The $503,072 worth of the 896 shares of Series DD Convertible
Preferred Stock is predicated on changing right into a quantity of totally paid and
nonassessable shares of frequent inventory decided by multiplying the quantity of
issued and excellent shares of frequent inventory of the Company on the date of
conversion by 3.17 conversion worth.



                                 Page 31 of 42




Depreciation and amortization elevated by $26,935 for the three months ended
September 30, 2022, in comparison with the identical interval in 2021, primarily on account of
completion of Cancun lab in May 2022.

General and administrative-related celebration expense lower by $8,116,269 for the
three months ended September 30, 2022, in comparison with the identical interval in 2021,
primarily because of the issuance of the 1,000 shares of the Company's Series CC
Convertible Preferred Stock to Lans Holdings Inc. terminated and changed with a
money fee as consideration. The Company paid Lans Holdings Inc., by supply
in escrow, an quantity equal to $8,200,000, offset by $83,731 the worth of the
1,000 shares of the Company's Series CC Convertible Preferred Stock terminated.



General and administrative expense improve by $55,257 for the three months
ended September 30, 2022, in comparison with the identical interval in 2021, primarily on account of
the acquisition of Global Stem Cells Group, Inc. on August 18, 2021.



Other expense



Other expense elevated by $282,251 for the three months ended September 30,
2022, in comparison with the identical interval in 2021, primarily in consequence of the rise
in curiosity on promissory notes. During the 9 months ended September 30,
2021, we acquired $11,400,000 in proceeds acquired from the issuance of
promissory notes. We anticipate different expense to extend in future quarters as a
outcome of the curiosity on the brand new debt.



Net Loss


We recorded a internet loss of $1,344,383 for the three months ended September 30,
2022
, as in contrast with a internet loss of $9,915,441 for a similar in 2021.

Results of Operations for the Nine Months Ended September 30, 2022 and 2021.

Below is a abstract of the outcomes of operations for the 9 months ended
September 30, 2022 and 2021.




                                                       For the Nine Months Ended September 30,
                                                2022             2021            $ Change       % Change
Revenue                                     $    988,958     $     185,254     $    803,704        433.84 %
Cost of income                                  468,838           115,170          353,668        307.08 %
Gross revenue                                     520,120            70,084          450,036        642.14 %

Operating bills
Advertising and advertising and marketing                        216,506            22,732 
        193,774        852.43 %
Professional charges                                735,186           665,544           69,642         10.46 %
Officer compensation                              67,500           552,932         (485,432 )      -87.79 %
Depreciation and
amortization expense                             102,184            13,347           88,837        665,59 %
Investor relations                               127,633            53,046           74,587        140.61 %
General and administrative- associated celebration              -         8,116,269       (8,116,269 )     -100.00 %
General and administrative                       341,131            69,206          271,925        392.92 %
Total working bills                       1,590,140         9,493,076 

(7,902,936 ) -83.25 %


Other revenue (expense)
Interest expense                              (3,454,874 )      (1,659,724 )      1,795,150        108.16 %
Derivative monetary
devices                                       10,482                 -           10,482          0.00 %
Other expense                                          -          (231,109 )        231,109       -100.00 %
Net loss                                    $ (4,514,412 )   $ (11,313,825 )   $  6,799,413        -60.10 %




                                 Page 32 of 42





Revenue


Revenue elevated by 433.84% within the quantity of $803,704 for the 9 months ended
September 30, 2022, in comparison with the identical interval in 2021. The key motive for the
improve in income was a outcome of the acquisition of Global Stem Cells Group,
Inc. on August 18, 2021. Revenue from viable cell remedy and immune assist
associated merchandise together with doctor coaching elevated by $810,384 offset by a
lower in sale of cash, metals and paper cash of $6,680 for the 9 months
ended September 30, 2022, in comparison with the identical interval in 2021.



Listed beneath are the revenues, price of revenues and gross income by Company for
the 9 months ended September 30, 2022:



                            For the Nine Months Ended
                               September 30, 2022
                   Global Stem          Meso
                   Cells Group       Numismatics        Total
Revenue           $     963,967     $      24,991     $ 988,958
Cost of income         445,814            23,024       468,838
Gross revenue      $     518,153     $       1,967     $ 520,120
Gross revenue %            53.75 %            7.87 %       52.59 %



We anticipate to extend our revenues in future quarters from our operations
related to Global Stem Cells with much less anticipated revenues in future quarters
related to our numismatic operations.



Operating bills


Operating bills decreased by 83.25% within the quantity of $7,902,936 for the 9
months ended September 30, 2022, in comparison with the identical interval in 2021. Listed
beneath are the key modifications to working bills:



Advertising and advertising and marketing charges elevated by $193,774 for the 9 months ended
September 30, 2022, in comparison with the identical interval in 2021, primarily because of the
acquisition of Global Stem Cells Group, Inc. on August 18, 2021.



Professional charges elevated by $69,642 for the 9 months ended September 30,
2022, in comparison with the identical interval in 2021, primarily on account of audit and accounting
bills.



Officer compensation decreased by $485,432 for the 9 months ended September
30, 2022, in comparison with the identical interval in 2021, primarily because of the issuance of
896 shares of Series DD Preferred Stock of the Company to Dave Christensen,
present Director, President, Chief Executive Officer, Chief Financial Officer
and Secretary as compensation pursuant to the Professional Service Consulting
Agreement. The $503,072 worth of the 896 shares of Series DD Convertible
Preferred Stock is predicated on changing right into a quantity of totally paid and
nonassessable shares of frequent inventory decided by multiplying the quantity of
issued and excellent shares of frequent inventory of the Company on the date of
conversion by 3.17 conversion worth.



Depreciation and amortization elevated by $88,837 for the 9 months ended
September 30, 2022, in comparison with the identical interval in 2021, primarily on account of
completion of Cancun lab in May 2022.

General and administrative-related celebration expense lower by $8,116,269 for the
9 months ended September 30, 2022, in comparison with the identical interval in 2021,
primarily because of the issuance of the 1,000 shares of the Company's Series CC
Convertible Preferred Stock to Lans Holdings Inc. terminated and changed with a
money fee as consideration. The Company shall pay Lans Holdings Inc., by
supply in escrow, an quantity equal to $8,200,000, offset by $83,731 the worth
of the 1,000 shares of the Company's Series CC Convertible Preferred Stock
terminated.



General and administrative expense improve by $271,925 for the 9 months
ended September 30, 2022, in comparison with the identical interval in 2021, primarily on account of
the acquisition of Global Stem Cells Group, Inc. on August 18, 2021.



                                 Page 33 of 42





Other expense



Other expense elevated by $1,553,559 for the 9 months ended September 30,
2022, in comparison with the identical interval in 2021, primarily in consequence of the rise
in curiosity on promissory notes. During the 9 months ended September 30,
2021, we acquired $11,400,000 in proceeds acquired from the issuance of
promissory notes. We anticipate different expense to extend in future quarters as a
outcome of the curiosity on the brand new debt.



Net Loss


We recorded a internet loss of $4,514,412 for the 9 months ended September 30,
2022
, as in contrast with a internet loss of $11,313,825 for a similar in 2021.

Liquidity and Capital Resources

Since inception, the Company has financed its operations by means of personal
placements and convertible notes. The following is a abstract of the money and
money equivalents as of September 30, 2022 and December 31, 2021.



                             September 30,       December 31,           $              %
                                 2022                2021             Change         Change
Cash and money equivalents   $     1,769,636     $    2,978,525     $ (1,208,889 )     -40.59 %

© Edgar Online, supply Glimpses



Source link

business | MSSV | US59071L1035 historical INC. stock exchange information MESO NUMISMATICS News other our press release purely relating statements than to
admin
  • Website

Related Posts

Top 5 Herbs to Kill Viruses and Boost Your Immune System

March 15, 2023

What Is the Immune System for Kids | Learn all about how the body fights off bad germs

March 14, 2023

The immune system: the body's natural defence | AFP

March 13, 2023

Leave A Reply Cancel Reply

Don't Miss
Brain Health

5 Best Yoga Poses for Your Lower Body and Brain Health

By adminMarch 15, 20230

Here are 5 nice asanas which are nice for your decrease physique and mind. Share…

Top 5 Herbs to Kill Viruses and Boost Your Immune System

March 15, 2023

Intermittent Fasting and Its Effects on the Brain | Ep. 82

March 14, 2023

What Is the Immune System for Kids | Learn all about how the body fights off bad germs

March 14, 2023
Stay In Touch
  • Facebook
  • Twitter
  • Pinterest
  • Instagram
  • YouTube
  • Vimeo
Our Picks

Custom Keto Diet Review – Maximise Fat Burning – luvgreenlife.com

November 12, 2022

Truth About Abs Review – luvgreenlife.com

November 12, 2022

Unlock Your Hip Flexors 2.0 Review – luvgreenlife.com Health Wellness

November 12, 2022

28-Day Keto Challenge – luvgreenlife.com

November 12, 2022

Subscribe to Updates

Get the latest creative news from SmartMag about art & design.

About Us
About Us

luvgreenlife.com is a health & fitness blog devoted to Immune support, Heart health, Colon cleanse detox, Weight loss and Brain health. We aim to provide the most current health information that is authoritative & trustworthy.

Subscribe to Updates

Get the latest creative news.

Categories
  • Brain Health
  • Colon Cleanse Detox
  • Heart Health
  • Immune Support
  • Reviews
  • Weight Loss
Facebook Twitter Instagram Pinterest
  • Home
  • Contact
  • Privacy Policy
  • Terms of use
  • Amazon Affiliate Disclaimer
© 2023 All rights reserved.

Type above and press Enter to search. Press Esc to cancel.